U.S. Intravenous Immunoglobulin (IVIG) Market Projected to Reach USD 10.2 Million by 2027

Rising Prevalence of Immunodeficiency Disorders and FDA Approvals Drive Market Expansion

The U.S. Intravenous Immunoglobulin (IVIG) Market Size is experiencing significant growth, with its valuation expected to increase from USD 6.48 million in 2020 to approximately USD 10.2 million by 2027, reflecting a compound annual growth rate (CAGR) of 6.8%.

Download your sample copy of this report today!https://www.maximizemarketresearch.com/request-sample/125228/ 

Market Definition and Overview

Intravenous Immunoglobulin (IVIG) is a therapeutic preparation derived from the serum of 1,000 to 15,000 donors per batch. It serves as a critical treatment for individuals with antibody deficiencies, providing necessary antibodies to bolster the immune system. Administered at replacement dosages of 200–400 mg/kg body weight every three weeks, IVIG addresses various immunodeficiency conditions, enhancing patients' quality of life and reducing susceptibility to infections.

To learn more about the findings of this research, please check:https://www.maximizemarketresearch.com/market-report/u-s-intravenous-immunoglobulin-market/125228/ 

Market Growth Drivers and Opportunities

Several factors are propelling the growth of the U.S. IVIG market:

  1. Increasing Prevalence of Immunodeficiency Disorders: Over 500,000 individuals in the United States are affected by more than 200 types of primary immunodeficiency diseases (PIDs). The rising incidence of both primary and acquired immunodeficiency conditions, such as AIDS and X-linked agammaglobulinemia, is driving the demand for immunoglobulin therapies.

  2. FDA Approvals and Introduction of Novel Therapies: The U.S. Food and Drug Administration (FDA) has been actively approving new IVIG products, enhancing treatment options for patients. For instance, in May 2019, ADMA Biologics, Inc. received FDA approval for its Prior Approval Supplement (PAS) for BIVIGAM, a 10% liquid IVIG indicated for primary humoral immunodeficiency. Similarly, in September 2017, CSL Behring obtained FDA approval for Privigen, an IVIG therapy for chronic inflammatory demyelinating polyneuropathy (CIDP).

  3. Advancements in Production and Purification Technologies: Innovations in the manufacturing processes of immunoglobulins have led to higher yields and improved safety profiles. Enhanced purification techniques reduce the risk of pathogen transmission and adverse reactions, making IVIG therapies more accessible and appealing to both healthcare providers and patients.

  4. Expansion of Therapeutic Indications: Beyond primary immunodeficiencies, IVIG is being explored and utilized for a broader range of conditions, including neurological disorders, autoimmune diseases, and acute infections. This expansion in therapeutic applications is opening new avenues for market growth and patient care.

Secure your sample copy of this report immediately!https://www.maximizemarketresearch.com/request-sample/125228/ 

Segmentation Analysis

The U.S. IVIG market can be segmented based on application and distribution channel:

  • By Application:

    • Immunodeficiency Diseases: This segment encompasses primary and secondary immunodeficiencies, where IVIG therapy is essential for providing the necessary antibodies that patients' bodies cannot produce sufficiently.
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A neurological disorder characterized by progressive weakness and impaired sensory function in the limbs, CIDP patients benefit from IVIG's immunomodulatory effects.
    • Immune Thrombocytopenic Purpura (ITP): An autoimmune disorder leading to low platelet counts, ITP patients receive IVIG to prevent bleeding complications.
    • Others: This includes conditions like Guillain-Barré syndrome, multifocal motor neuropathy, and Kawasaki disease, where IVIG has shown therapeutic benefits.

  • By Distribution Channel:

    • Hospital Pharmacies: Hospitals dispense IVIG therapies for inpatient and outpatient treatments, ensuring immediate availability for acute care.
    • Specialty Pharmacies: These pharmacies focus on complex and chronic conditions, providing IVIG therapies with specialized handling and patient support services.
    • Home Healthcare: With the increasing preference for home-based treatments, home healthcare services administer IVIG infusions, offering convenience and comfort to patients.

Obtain your sample copy of this report now!https://www.maximizemarketresearch.com/request-sample/125228/ 

Competitive Landscape

The U.S. IVIG market is characterized by the presence of several key players focusing on research, development, and distribution of immunoglobulin therapies. Notable companies include:

  • ADMA Biologics, Inc.: A biopharmaceutical company specializing in the development and commercialization of plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

  • CSL Behring: A global leader in biotherapeutics, CSL Behring offers a comprehensive portfolio of immunoglobulin products, including Privigen, catering to various therapeutic needs.

  • Grifols S.A.: A multinational pharmaceutical company that produces a range of plasma-derived products, Grifols is committed to enhancing patient care through innovative immunoglobulin therapies.

  • Kedrion Biopharma Inc.: Specializing in the collection and fractionation of blood plasma, Kedrion provides immunoglobulin products aimed at treating immune system deficiencies and related conditions.

Our Trending Related Report :

Smart watch Market https://www.maximizemarketresearch.com/market-report/global-smartwatch-market/20374/ 
Breast Imaging Market https://www.maximizemarketresearch.com/market-report/global-breast-imaging-market/21004/ 

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

sales@maximizemarketresearch.com 

+91 96071 95908, +91 9607365656